```
     FILE 'REGISTRY' ENTERED AT 15:18:33 ON 03 SEP 2008
L1                STRUCTURE UPLOADED
L2              0 S L1
L3              6 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 15:19:39 ON 03 SEP 2008
L4              6 S L3
```

=>
Uploading C:\Program Files\STNEXP\Queries\10546132markush.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
49 50 51 52
53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73
74 76 78 85
87
ring nodes :
1 2 3 4 5 6
chain bonds :
1-10 1-69 2-11 2-68 3-7 3-72 5-9 5-71 6-8 6-70 7-76 8-85 9-87 10-47
11-78 12-13 12-45 13-14 14-15 14-46 15-16 16-17 17-18 18-19 19-20 20-21
21-22 22-23
23-24 24-25 26-27 26-44 27-28 28-29 29-30 30-31 31-32 32-33 33-34 34-35
35-36 36-37 36-73
37-38 37-74 38-39 39-40 40-41 41-42 42-43 47-48 48-49 49-50 49-57 49-58
50-51 51-52
52-53 53-54 54-55 55-56 59-60 59-66 60-61 60-65 62-63 63-64 64-67
ring bonds :

```
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  1-10  2-3  2-11  3-4  4-5  5-6  5-9  6-8  7-76  8-85  9-87  11-78  12-45
14-46  26-44  49-57  63-64
exact bonds :
1-69  2-68  3-7  3-72  5-71  6-70  10-47  12-13  13-14  14-15  15-16  16-17  17-18
18-19  19-20  20-21  21-22  22-23  23-24  24-25  26-27  27-28  28-29  29-30  30-31
31-32  32-33
33-34  34-35  35-36  36-37  36-73  37-38  37-74  38-39  39-40  40-41  41-42  42-43
47-48  48-49
49-50  49-58  50-51  51-52  52-53  53-54  54-55  55-56  59-60  59-66  60-61  60-65
62-63  64-67



G1:H,Si,CH3

G2:H,P

G3:H,MeO

G4:[*1],[*2]

G5:[*3],[*4]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS
21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
29:CLASS  30:CLASS
31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS
39:CLASS  40:CLASS
41:CLASS  42:CLASS  43:CLASS  44:CLASS  45:CLASS  46:CLASS  47:CLASS  48:CLASS
49:CLASS  50:CLASS
51:CLASS  52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  58:CLASS
59:CLASS  60:CLASS
61:CLASS  62:CLASS  63:CLASS  64:CLASS  65:CLASS  66:CLASS  67:CLASS  68:CLASS
69:CLASS
70:CLASS  71:CLASS  72:CLASS  73:CLASS  74:CLASS  76:CLASS  78:CLASS  85:CLASS
87:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 15:19:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       85 TO ITERATE

100.0% PROCESSED       85 ITERATIONS                                0 ANSWERS
```

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1147 TO 2253
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:19:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2031 TO ITERATE

100.0% PROCESSED 2031 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L3 6 SEA SSS FUL L1

=> d l3 scan

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-
MF C33 H61 N O7

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]-
MF C39 H75 N O7 Si

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN β-D-Glucopyranoside, (1E)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]-
MF C39 H75 N O7 Si

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-
MF C39 H73 N O7

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.82	179.03

FILE 'HCAPLUS' ENTERED AT 15:19:39 ON 03 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Sep 2008 VOL 149 ISS 10
FILE LAST UPDATED: 2 Sep 2008 (20080902/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 6 L3

=> d l4 1-6 ti abs bib hitstr

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Sodium salt of glucosamine disaccharide compound, method for producing the same, and use of the same
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed a sodium salt represented by the average formula (I; m1, n1, m2 and n2 independently represent 0 or a pos. number not more than 2, while satisfying m1 + n1 =2, m2 + n2 =2, 0 < m1 + m2 < 4 and 0 < n1 + n2 < 4.) and a method for producing such a sodium salt. There is also a decomposition suppressing method which enables to have a sodium salt represented by the average formula I coexistent with a sodium salt represented by the general formula II below. This method enables to improve long-term stability of a sodium salt represented by the general formula II which is effective for the prevention and/or treatment of septicemia caused by gram pos. bacteria, in particular endotoxin shock. Thus, a DEAE column main fraction containing 6.0 g disaccharide free acid (III) (preparation given) and 4.80
weight% Na and 942.8 L MeOH were stirred in a 4 L flask at 25°, treated with 0.2 N NaOH/MeOH solution (15.2 mL), stirred overnight, filtered, and treated dropwise with 270 mL acetone at 25°. The precipitate was removed by filtration and dried in vacuo to give III.3.67 Na. When III.3.67 Na was stored in a screw-cap bottle at 25° for 30 days, impurities A, B, and C were formed at a rate of 0.072, 0.267, and 0.072 %/mo, resp., vs. 0.729. 3.117, and 0.033 %/mo, resp., for III.4.06Na.

AN 2008:636616 HCAPLUS <<LOGINID::20080903>>

DN 149:10241

TI Sodium salt of glucosamine disaccharide compound, method for producing the same, and use of the same

IN Sakurai, Shin; Furukawa, Ken; Matsuo, Kimihiro; Tagami, Kenichi

PA Eisai R & D Management Co., Ltd., Japan

SO PCT Int. Appl., 46pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008062842	A1	20080529	WO 2007-JP72579	20071121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	JP 2006-315020	A	20061122		
	US 2006-860483P	P	20061122		

IT 748165-18-6P 748165-20-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of sodium salt of glucosamine disaccharide compound
with storage stability, method for producing it, and its use for prevention and/or treatment of endotoxin shock)

RN 748165-18-6 HCAPLUS

CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-20-0 HCAPLUS
CN α-D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) 1-(2,2,2-trichloroethanimidate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 748165-17-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sodium salt of glucosamine disaccharide compound with storage
stability, method for producing it, and its use for prevention and/or treatment of endotoxin shock)
RN 748165-17-5 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Process for production of lipid A analogue
GI



I

AB There is disclosed a process for producing 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-α-D-glucopyranose 1-(dihydrogen phosphate) (known as eritoran) tetrasodium salt (I; R = PO3Na2) which is useful as an active ingredient of a pharmaceutical or an intermediate for the synthesis thereof. A process for producing the compound I (R = PO3Na2) comprises the key steps of reacting a compound represented by the formula I [R = P(O)(OCH2CH:CH2)2] with a palladium catalyst in the presence of a nucleophilic agent (deallylation) and treating the product with a sodium source (sodium salt formation). This process is environment-friendly and excellent in safety, operationability, and reproducibility. Thus, a solution of 101.6 g I [R = P(O)(OCH2CH:CH2)2] in 203 mL THF was added to a mixture of Meldrum's acid 70.49, palladium acetate 2.93, and PPh3 51.3 g and the resulting mixture was stirred at 32° for 2 h and at 30° for 4 h, treated with 250 mL MeOH, and concentrated under reduced pressure to give a residue (466.7 g). The residue was dissolved in 4,570 mL MeOH at 40°, treated with

5.55 g trimercaptotriazine, stirred overnight at room temperature, and filtered to remove the precipitated trimercaptotriazine-palladium complex, followed by washing the precipitate with MeOH to give a combined filtrate (4,330 g). The filtrate (3,908.2 mL) was concentrated under reduced pressure to give a residue (440.9 g) which was treated with 450 mL acetone, concentrated under reduced pressure, treated again with 450 mL acetone, and concentrated under reduced pressure. The residue was refrigerated overnight, treated with 1,800 mL acetone, warmed to 40°, stirred for 1.5 h, air-cooled, stirred at ≥30° for 1.5 h, and filtered to give, after washing with acetone and drying at 35-40° under reduced pressure, 74.2% eritoran (free acid form) which was treated with 0.1 N aqueous NaOH solution to give eritoran tetrasodium salt.

AN 2007:257680 HCAPLUS <<LOGINID::20080903>>
DN 146:317153
TI Process for production of lipid A analogue
IN Tagami, Katsuya; Sato, Keizo; Matsuo, Kimihiro; Abe, Taichi; Haga, Toyokazu
PA Eisai R & D Management Co., Ltd., Japan
SO PCT Int. Appl., 69pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007026675	A1	20070308	WO 2006-JP316941	20060829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006285926	A1	20070308	AU 2006-285926	20060829
CA 2620027	A1	20070308	CA 2006-2620027	20060829
EP 1939209	A1	20080702	EP 2006-796921	20060829
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR 2008039374	A	20080507	KR 2008-700572	20080109
CN 101238140	A	20080806	CN 2006-80027144	20080124
PRAI US 2005-712431P	P	20050831		
JP 2005-253044	A	20050901		
WO 2006-JP316941	W	20060829		

OS CASREACT 146:317153
IT 748165-18-6P 748165-20-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for production of lipid A analog (eritoran) via palladium-catalyzed deallylation of eritoran diallyl ester and formation of sodium salt)
RN 748165-18-6 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-20-0 HCAPLUS
CN α-D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) 1-(2,2,2-trichloroethanimidate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 748165-17-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for production of lipid A analog (eritoran) via palladium-catalyzed deallylation of eritoran diallyl ester and formation of sodium salt)
RN 748165-17-5 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of glucose lipid A analogs inhibiting macrophage activity
GI



I

AB Title compds. I [Q = -O-, alkylene, -O-alkylene, etc.; W = -O- or -NH-; when W is -NH-, R1 is alkanoyl, alkenoyl, alkynoyl. (wherein alkanoyl, alkenoyl and alkynoyl are optionally substituted with halo, hydroxy, oxo, etc.); each R1 (when W is -O-), R2, R3, and R4 is H, alkyl, alkenyl, etc. (wherein alkyl and alkenyl are optionally substituted with halo, hydroxy, oxo, etc.); R5 = H, halo, hydroxy, etc.] and their pharmacol. acceptable salts were prepared For example, phosphono 3-O-decyl-2-deoxy-6-O-[3-O-[(R)-3-methoxydecyl]-6-O-methyl-2-O-[(Z)-11-octadecenoyl]-4-O-phosphono-β-D-glucopyranosyl]-2-(3-oxotetradecanoylamino)-α-D-glucopyranoside (II) was prepared from 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose in 18 steps. In human TNFα production inhibition assays, the IC50 value of compound II was 0.49 nM. Compds. I are claimed useful for the treatment of inflammation, autoimmune diseases, etc.
AN 2007:167289 HCAPLUS <<LOGINID::20080903>>
DN 146:252059
TI Preparation of glucose lipid A analogs inhibiting macrophage activity
IN Shiozaki, Masao; Shimozato, Ryuichi
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 86pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2007039450	A	20070215	JP 2006-187298	20060707
PRAI	JP 2005-199518	A	20050708		

OS MARPAT 146:252059
IT 859508-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of glucose lipid analogs for treatment of inflammation and autoimmune diseases)
RN 859508-28-4 HCAPLUS
CN β-D-Glucopyranoside, (1E)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Syntheses of glucose-containing E5564 analogs and their LPS-antagonistic activities
AB Lipid A analogs containing a glucose moiety on their non-reducing end were synthesized, and their LPS-antagonistic activities were measured. The inhibitory activities (IC50) on LPS-induced TNFα production of title aminodeoxy disaccharides toward human whole blood cells were 0.46-1.11 nM. Inhibitory doses (ID50) of these compds. on TNFα production induced by co-injection of galactosamine and LPS in C3H/HeN mice were measured. The ID50 values of these compds. were 0.20-1.08 and <0.2 mg/kg. Moreover, C3H/HeN mice preinjected with compds. were protected from lethality induced by co-injection of galactosamine and LPS. Out of eight mice preinjected with 1 mg/kg of title compds. five-eight mice were protected.
AN 2005:1299295 HCAPLUS <<LOGINID::20080903>>
DN 144:171174
TI Syntheses of glucose-containing E5564 analogs and their LPS-antagonistic activities
AU Shiozaki, Masao; Doi, Hiromi; Tanaka, Daisuke; Shimozato, Takaichi; Kurakata, Shin-ichi
CS Chemistry Department, Chemtech Labo, Inc., Hiromachi 1-2-58, Shinagawa-ku, Tokyo, 140-8710, Japan
SO Tetrahedron (2005), Volume Date 2006, 62(1), 205-225
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:171174
IT 859508-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(syntheses of glucose-containing E5564 analogs and their LPS-antagonistic activities)

RN 859508-28-4 HCAPLUS
CN β-D-Glucopyranoside, (1E)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
TI preparation of levulose glucoselipid A derivatives as TNFα production inhibitors
GI



I

AB Title compds. I [Q = O, etc.; W = O, NH; R1 = (un)substituted alkanoyl, etc. with the proviso that if W = NH; R1 (with the proviso that if W = O), R2, R3, R4 = H, (un)sunstituted alkyl, etc.; R5 = H, halo, etc.] were prepared For example, phosphorylation of 4-O-(allyloxycarbonyl)-3-O-decyl-2-deoxy-6-O-[4-O-diallylphosphono-3-O-[(R)-3-methoxydecyl]-6-O-methyl-2-O-[(Z)-11-octadecenoyl]-β-D-glucopyranosyl]-2-(3-oxotetradecanoylamino)-α-D-glucopyranoside, e.g., prepared from 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose in 15 steps, with diallyl diisopropylphosphoramidate followed by deallylation using Pd(PPh3)4 afforded phosphono 3-O-decyl-2-deoxy-6-O-[3-O-[(R)-3-methoxydecyl]-6-O-methyl-2-O-[(Z)-11-octadecenoyl]-4-O-phosphono-β-D-glucopyranosyl]-2-(3-oxotetradecanoylamino)-α-D-glucopyranoside (II). In TNFα production inhibition assays, the IC50 value of compound II was 0.49 nM. Compds. I are claimed useful for the treatment of inflammation, septicemia, etc.

AN 2005:638895 HCAPLUS <<LOGINID::20080903>>
DN 143:153644
TI preparation of levulose glucoselipid A derivatives as TNFα production inhibitors
IN Shiozaki, Masao; Shimozato, Takaichi
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066193	A1	20050721	WO 2005-JP434	20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2552218	A1	20050721	CA 2005-2552218	20050107
	JP 2005220130	A	20050818	JP 2005-2028	20050107
	EP 1702926	A1	20060920	EP 2005-703673	20050107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1930180	A	20070314	CN 2005-80007429	20050107
	BR 2005006671	A	20070515	BR 2005-6671	20050107
	IN 2006KN01892	A	20070511	IN 2006-KN1892	20060706
	MX 2006PA07822	A	20060926	MX 2006-PA7822	20060707
PRAI	JP 2004-2902	A	20040108		
	WO 2005-JP434	W	20050107		

OS MARPAT 143:153644
IT 859508-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of levulose glucoselipid A derivs. as TNFα production inhibitors for treatment of inflammation, septicemia, etc.)
RN 859508-28-4 HCAPLUS
CN β-D-Glucopyranoside, (1E)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Reagents and methods for preparing lipopolysaccharides antagonist B1287 and stereoisomers thereof for treatment of various forms of septic shock
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides methods for preparing lipopolysaccharides (LPS) antagonist lipo-disaccharide B1287 and stereoisomers thereof, which compds. are useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock (no biol. data). Also provided are synthetic intermediates useful for implementing the inventive methods. Thus, lipo-disaccharide B1287 I was prepared for treatment of various forms of septic shock.
AN 2004:718552 HCAPLUS <<LOGINID::20080903>>
DN 141:225771
TI Reagents and methods for preparing lipopolysaccharides antagonist B1287 and stereoisomers thereof for treatment of various forms of septic shock
IN Fan, Rulin
PA Eisai Co, Ltd., Japan
SO PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004074303	A2	20040902	WO 2004-US4921	20040218
	WO 2004074303	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2006518394	T	20060810	JP 2006-503710	20040218
	US 20060160999	A1	20060720	US 2005-546132	20051212
PRAI	US 2003-448839P	P	20030220		
	WO 2004-US4921	W	20040218		

OS CASREACT 141:225771; MARPAT 141:225771
IT 748165-17-5P 748165-18-6P 748165-20-0P
748165-24-4P 748165-25-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reagents and methods for preparing lipopolysaccharides antagonist b and stereoisomers thereof for treatment of various forms of septic shock)
RN 748165-17-5 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 748165-18-6 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-20-0 HCAPLUS
CN α-D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) 1-(2,2,2-trichloroethanimidate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-24-4 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-25-5 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.